$2.42 Billion is the total value of Rock Springs Capital Management LP's 131 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 38.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $116,799,000 | -15.0% | 1,349,500 | +5.6% | 4.83% | +11.3% |
| BIIB | New | BIOGEN INC | $56,948,000 | – | 180,000 | +100.0% | 2.36% | – |
| IRTC | Buy | IRHYTHM TECHNOLOGIES INC | $52,471,000 | +23.5% | 645,000 | +3.4% | 2.17% | +61.7% |
| BAX | Buy | BAXTER INTL INC | $52,368,000 | +19.3% | 645,000 | +22.9% | 2.16% | +56.1% |
| PODD | Buy | INSULET CORP | $48,379,000 | +8.5% | 292,000 | +12.1% | 2.00% | +41.9% |
| HCA | Buy | HCA HEALTHCARE INC | $46,722,000 | -32.4% | 520,000 | +11.2% | 1.93% | -11.5% |
| CNC | Buy | CENTENE CORP DEL | $44,558,000 | +208.4% | 750,000 | +226.4% | 1.84% | +303.9% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $43,306,000 | +51.1% | 1,025,000 | +53.0% | 1.79% | +97.7% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $43,100,000 | +40.8% | 737,000 | +92.9% | 1.78% | +84.3% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $41,526,000 | -0.9% | 381,500 | +4.8% | 1.72% | +29.6% |
| ZLAB | Buy | ZAI LAB LTDadr | $38,610,000 | +48.5% | 750,000 | +20.0% | 1.60% | +94.4% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $37,449,000 | +22.3% | 1,055,500 | +64.5% | 1.55% | +59.9% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $36,592,000 | -14.5% | 194,000 | +5.7% | 1.51% | +11.8% |
| NVRO | Buy | NEVRO CORP | $34,593,000 | +5.5% | 346,000 | +24.0% | 1.43% | +38.0% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $33,225,000 | +11.1% | 747,800 | +6.8% | 1.37% | +45.4% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $32,110,000 | +12.5% | 380,000 | +12.6% | 1.33% | +47.2% |
| IDXX | Buy | IDEXX LABS INC | $30,280,000 | -3.5% | 125,000 | +4.0% | 1.25% | +26.2% |
| APLT | Buy | APPLIED THERAPEUTICS INC | $27,646,000 | +4890.3% | 845,700 | +4062.9% | 1.14% | +6250.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $26,251,000 | -32.1% | 341,500 | +13.8% | 1.08% | -11.1% |
| FRPT | Buy | FRESHPET INC | $25,388,000 | +20.9% | 397,500 | +11.9% | 1.05% | +58.4% |
| CI | Buy | CIGNA CORP NEW | $24,982,000 | +62.9% | 141,000 | +88.0% | 1.03% | +113.0% |
| EXAS | Buy | EXACT SCIENCES CORP | $24,592,000 | -36.7% | 424,000 | +1.0% | 1.02% | -17.1% |
| ALGN | Buy | ALIGN TECHNOLOGY INC | $22,179,000 | -28.3% | 127,500 | +15.0% | 0.92% | -6.2% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $17,333,000 | +2.2% | 750,000 | +14.5% | 0.72% | +33.8% |
| HQY | Buy | HEALTHEQUITY INC | $15,430,000 | +1.6% | 305,000 | +48.8% | 0.64% | +32.9% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $14,305,000 | -32.1% | 280,000 | +5.7% | 0.59% | -11.3% |
| IMMU | Buy | IMMUNOMEDICS INC | $14,154,000 | -33.1% | 1,050,000 | +5.0% | 0.58% | -12.6% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $12,491,000 | -41.9% | 1,751,900 | +94.7% | 0.52% | -24.0% |
| INSP | New | INSPIRE MED SYS INC | $12,056,000 | – | 200,000 | +100.0% | 0.50% | – |
| NVCR | Buy | NOVOCURE LTD | $11,785,000 | -18.9% | 175,000 | +1.4% | 0.49% | +6.1% |
| ARVN | Buy | ARVINAS INC | $11,486,000 | +11.8% | 285,000 | +14.0% | 0.48% | +46.2% |
| HCAT | Buy | HEALTH CATALYST INC | $11,114,000 | +100.2% | 425,000 | +165.6% | 0.46% | +162.9% |
| New | CYTOKINETICS INCnote 4.000%11/1 | $10,573,000 | – | 8,000,000 | +100.0% | 0.44% | – | |
| CNMD | New | CONMED CORP | $10,309,000 | – | 180,000 | +100.0% | 0.43% | – |
| ZGNX | Buy | ZOGENIX INC | $9,892,000 | -24.1% | 400,000 | +60.0% | 0.41% | -0.7% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $8,580,000 | -27.1% | 5,500,000 | +0.0% | 0.36% | -4.6% |
| PPD | New | PPD INC | $8,015,000 | – | 450,000 | +100.0% | 0.33% | – |
| MYOK | Buy | MYOKARDIA INC | $7,735,000 | -33.7% | 165,000 | +3.1% | 0.32% | -13.0% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $7,610,000 | -3.9% | 500,000 | +44.9% | 0.32% | +26.0% |
| IMRA | New | IMARA INC | $7,148,000 | – | 445,936 | +100.0% | 0.30% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $5,670,000 | – | 500,000 | +100.0% | 0.23% | – |
| PRTA | New | PROTHENA CORP PLC | $5,350,000 | – | 500,000 | +100.0% | 0.22% | – |
| STAA | New | STAAR SURGICAL CO | $5,000,000 | – | 155,000 | +100.0% | 0.21% | – |
| CHMA | Buy | CHIASMA INC | $4,928,000 | -14.4% | 1,350,000 | +16.4% | 0.20% | +12.1% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $4,888,000 | -3.2% | 605,000 | +15.2% | 0.20% | +27.0% |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $4,860,000 | – | 250,000 | +100.0% | 0.20% | – |
| PRTK | Buy | PARATEK PHARMACEUTICALS INC | $4,808,000 | +218.2% | 1,526,310 | +307.0% | 0.20% | +314.6% |
| TXG | Buy | 10X GENOMICS INC | $4,736,000 | -14.3% | 76,000 | +4.8% | 0.20% | +12.0% |
| OSW | Buy | ONESPAWORLD HOLDINGS LIMITED | $4,263,000 | -71.9% | 1,050,000 | +16.7% | 0.18% | -63.3% |
| ANAB | Buy | ANAPTYSBIO INC | $4,239,000 | +93.2% | 300,000 | +122.2% | 0.18% | +153.6% |
| IMVT | New | IMMUNOVANT INC | $3,891,000 | – | 250,000 | +100.0% | 0.16% | – |
| PASG | New | PASSAGE BIO INC | $3,544,000 | – | 225,000 | +100.0% | 0.15% | – |
| OBSV | Buy | OBSEVA SA | $3,374,000 | +11.9% | 1,400,000 | +77.3% | 0.14% | +47.4% |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $3,264,000 | +240.0% | 1,200,000 | +50.0% | 0.14% | +350.0% |
| New | TRILLIUM THERAPEUTICS INC | $3,030,000 | – | 750,000 | +100.0% | 0.12% | – | |
| GWPH | New | GW PHARMACEUTICALS PLCads | $2,627,000 | – | 30,000 | +100.0% | 0.11% | – |
| New | RETROPHIN INCnote 2.500% 9/1 | $2,566,000 | – | 3,250,000 | +100.0% | 0.11% | – | |
| XLRN | New | ACCELERON PHARMA INC | $1,573,000 | – | 17,500 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.